Cassava sciences resolves sec investigation

Austin, texas, sept. 26, 2024 (globe newswire) -- cassava sciences, inc. (“cassava” or the “company”) (nasdaq: sava), a biotechnology company focused on alzheimer's disease, today announced that it has reached a settlement with the u.s. securities and exchange commission (“sec”) of negligence-based disclosure charges that resolve a previously-disclosed sec investigation into statements made by the company pertaining to the results of its 2020 phase 2b clinical trial of simufilam and related matters. two former senior employees of the company also settled negligence-based disclosure charges brought by the sec.
sava Ratings Summary
sava Quant Ranking